AngioDynamics, a medical technology company specializing in vascular health and cancer treatment, has initiated a global registry study to assess the long-term effectiveness of the NanoKnife System in treating men with intermediate-risk prostate cancer. This study is being conducted in collaboration with University College London Hospital (UCLH), a leading institution in robotic prostate surgery and focal therapy.
Intermediate-risk prostate cancer represents a significant portion of diagnoses, and traditional treatments like surgery or radiotherapy often lead to complications such as urinary incontinence and erectile dysfunction. The NanoKnife System presents a less invasive alternative, utilizing irreversible electroporation (IRE) technology to eliminate targeted cells without heat. This method aims to preserve surrounding healthy tissue and minimize adverse effects on quality of life.
The NICE in the U.K. recently reclassified the NanoKnife System from “Research Only” to “Special Arrangements,” permitting broader usage while data collection continues. This shift reflects the growing recognition of this technology within national urology guidelines. The international registry study, aiming to enroll at least 500 participants, builds upon existing single-center studies demonstrating the system’s safety and efficacy in treating tumors and potentially delaying the need for radical intervention.
This research aligns with ongoing randomized controlled trials comparing NanoKnife to radical treatments. By meticulously monitoring patients after treatment, the study will assess quality of life, overall survival, prostate-specific mortality, and the need for any subsequent interventions. The findings will contribute to a more comprehensive understanding of the NanoKnife System’s role in prostate cancer treatment, potentially paving the way for wider adoption and improved patient care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
